Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer
Introduction In addition to reduced nectin‐4 expression, the upregulation of ATP‐binding cassette transporters has been suggested as a potential mechanism of resistance to enfortumab vedotin. Case presentation A 76‐year‐old man previously treated with platinum‐containing chemotherapy and pembrolizum...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12696 |
| _version_ | 1797280244522024960 |
|---|---|
| author | Mariko Kotono Toshiki Kijima Atsuko Takada‐Owada Naoya Okubo Ryo Kurashina Hidetoshi Kokubun Toshitaka Uematsu Kohei Takei Kazuyuki Ishida Takao Kamai |
| author_facet | Mariko Kotono Toshiki Kijima Atsuko Takada‐Owada Naoya Okubo Ryo Kurashina Hidetoshi Kokubun Toshitaka Uematsu Kohei Takei Kazuyuki Ishida Takao Kamai |
| author_sort | Mariko Kotono |
| collection | DOAJ |
| description | Introduction In addition to reduced nectin‐4 expression, the upregulation of ATP‐binding cassette transporters has been suggested as a potential mechanism of resistance to enfortumab vedotin. Case presentation A 76‐year‐old man previously treated with platinum‐containing chemotherapy and pembrolizumab for metastatic bladder cancer was administered enfortumab vedotin because of disease progression. Subsequently, metastasectomy was performed for oligometastatic lesions (in the lung and adrenal gland) that exhibited growth during enfortumab vedotin therapy. Immunostaining analysis revealed decreased nectin‐4 expression and elevated MDR1, MRP1, and BCRP expression in the metastatic lesions. Conclusion Decreased nectin‐4 expression and increased ATP‐binding cassette transporter expression are potential factors in the development of enfortumab vedotin resistance in urothelial carcinoma. Immunohistochemical evaluation of these proteins may aid in predicting treatment efficacy. |
| first_indexed | 2024-03-07T16:37:24Z |
| format | Article |
| id | doaj.art-63bcc92766b349b79fab938d17d6b54a |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-03-07T16:37:24Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-63bcc92766b349b79fab938d17d6b54a2024-03-03T09:26:39ZengWileyIJU Case Reports2577-171X2024-03-017217317610.1002/iju5.12696Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancerMariko Kotono0Toshiki Kijima1Atsuko Takada‐Owada2Naoya Okubo3Ryo Kurashina4Hidetoshi Kokubun5Toshitaka Uematsu6Kohei Takei7Kazuyuki Ishida8Takao Kamai9Department of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Diagnostic Pathology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Diagnostic Pathology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanIntroduction In addition to reduced nectin‐4 expression, the upregulation of ATP‐binding cassette transporters has been suggested as a potential mechanism of resistance to enfortumab vedotin. Case presentation A 76‐year‐old man previously treated with platinum‐containing chemotherapy and pembrolizumab for metastatic bladder cancer was administered enfortumab vedotin because of disease progression. Subsequently, metastasectomy was performed for oligometastatic lesions (in the lung and adrenal gland) that exhibited growth during enfortumab vedotin therapy. Immunostaining analysis revealed decreased nectin‐4 expression and elevated MDR1, MRP1, and BCRP expression in the metastatic lesions. Conclusion Decreased nectin‐4 expression and increased ATP‐binding cassette transporter expression are potential factors in the development of enfortumab vedotin resistance in urothelial carcinoma. Immunohistochemical evaluation of these proteins may aid in predicting treatment efficacy.https://doi.org/10.1002/iju5.12696ABC transportersantibody‐drug conjugateenfortumab vedotinnectin‐4urothelial cancer |
| spellingShingle | Mariko Kotono Toshiki Kijima Atsuko Takada‐Owada Naoya Okubo Ryo Kurashina Hidetoshi Kokubun Toshitaka Uematsu Kohei Takei Kazuyuki Ishida Takao Kamai Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer IJU Case Reports ABC transporters antibody‐drug conjugate enfortumab vedotin nectin‐4 urothelial cancer |
| title | Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer |
| title_full | Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer |
| title_fullStr | Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer |
| title_full_unstemmed | Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer |
| title_short | Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer |
| title_sort | increased expression of atp binding cassette transporters in enfortumab vedotin resistant urothelial cancer |
| topic | ABC transporters antibody‐drug conjugate enfortumab vedotin nectin‐4 urothelial cancer |
| url | https://doi.org/10.1002/iju5.12696 |
| work_keys_str_mv | AT marikokotono increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT toshikikijima increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT atsukotakadaowada increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT naoyaokubo increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT ryokurashina increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT hidetoshikokubun increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT toshitakauematsu increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT koheitakei increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT kazuyukiishida increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer AT takaokamai increasedexpressionofatpbindingcassettetransportersinenfortumabvedotinresistanturothelialcancer |